| scholarly article | Q13442814 |
| P50 | author | T Yau | Q56997342 |
| P2093 | author name string | Ronnie T P Poon | |
| Hilda Wong | |||
| Pierre Chan | |||
| Roberta Pang | |||
| Sheung Tat Fan | |||
| T J Yao | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Prognosis of hepatocellular carcinoma: the BCLC staging classification | Q29619984 | ||
| What do we mean by validating a prognostic model? | Q33849998 | ||
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 | ||
| Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. | Q37646457 | ||
| Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | Q43008115 | ||
| Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. | Q46183882 | ||
| alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma | Q46642643 | ||
| Hepatocellular carcinoma | Q57696098 | ||
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
| New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy | Q82877410 | ||
| Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma | Q84184595 | ||
| Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment | Q84514597 | ||
| Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival | Q84634948 | ||
| P433 | issue | 9 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1270-1279 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib | |
| P478 | volume | 16 |
| Q26851033 | Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up |
| Q35872656 | Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis. |
| Q84324837 | An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma |
| Q97652850 | Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma |
| Q41879721 | Biomarkers and Personalized Sorafenib Therapy |
| Q37708002 | Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. |
| Q54208538 | Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. |
| Q26783895 | Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging |
| Q53147159 | Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. |
| Q33403870 | Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis |
| Q36299617 | Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development |
| Q38246965 | Hepatocellular carcinoma: systemic therapies and future perspectives |
| Q34550662 | Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma |
| Q37696374 | Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation |
| Q38042711 | Impact of restricting access to high-cost medications for hepatocellular carcinoma. |
| Q92658310 | Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study |
| Q40707153 | Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma |
| Q48226736 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. |
| Q42980163 | Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report |
| Q36181200 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy |
| Q35821594 | Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma |
| Q38988884 | Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura |
| Q38282800 | New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions |
| Q84704956 | Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC) |
| Q87167977 | Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice |
| Q40227841 | Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. |
| Q90694554 | Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma |
| Q92367636 | Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis |
| Q43950860 | Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design |
| Q37088265 | Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? |
| Q26784218 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? |
| Q43244774 | Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma |
| Q53123123 | Recent topics on α-fetoprotein. |
| Q53089236 | Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction. |
| Q90436245 | Review article: systemic treatment of hepatocellular carcinoma |
| Q64911371 | Sorafenib for the treatment of hepatocellular carcinoma. |
| Q38830457 | Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. |
| Q39019421 | Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors |
| Q53346098 | Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy. |
| Q57067866 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? |
| Q39403970 | The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma |
| Q94606142 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib |
| Q37255838 | Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations |
| Q57491231 | Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy |
| Q47818290 | Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. |
| Q54936806 | Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. |
Search more.